Drugs / FOLFIRI Protocol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03168607 | May 2017 → May 2019 | neuroendocrine carcinoma | Peking University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05605509 Comparator | May 2023 → Nov 2025 | cancer of unknown primary site | Canadian Cancer Trials Group | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOLFIRI Protocol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03168607 ↗ |